No Data
Healthcare Stocks With A+ Momentum Investors Are Watching
Relay Therapeutics, Inc. (NASDAQ:RLAY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Oppenheimer Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $18
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $18 to $21
Analysts Offer Insights on Healthcare Companies: Revvity (RVTY) and Relay Therapeutics (RLAY)
Relay Therapeutics | 8-K: Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates